What’s Going On With Geyser Maker A.O.Smith Shares Today?
AOS reported 6% Y/Y revenue growth in Q4, beating consensus. North American sales up 7%, rest of world up 4%. Adjusted EPS of $0.97 also beat consensus.
Life Science Giant Danaher Warns Of Sales Decline In 2024; Says ‘Pandemic Has Transitioned To An Endemic State’
Danaher reported Q4 2023 adjusted EPS of $2.09, exceeding consensus of $1.89. Sales decreased 10% Y/Y to $6.4B. Non-GAAP core revenue declined 11.5%. Guidance for core revenue growth will continue, but not for base business core revenue.
Why Is Hospital Chain HCA Healthcare Stock Trading Higher Today?
HCA Healthcare surpasses Q4 2023 revenue expectations at $17.30B. CEO Sam Hazen highlights strong demand, increased ER visits, and improved financial performance. Mike Marks appointed as new CFO.
Qualcomm Q1 Earnings Preview: Analysts Focus On Automotive Growth, AI, Stock Valuation
Qualcomm reports Q1 earnings on Jan. 31. The San Diego-based company expects $2.37 EPS and $9.5 billion in revenues, touting AI growth potential.
Why Is Vertex Pharmaceuticals Stock Sliding Today?
Explore Vertex Pharmaceuticals' Phase 3 results for VX-548, a NaV1.8 inhibitor, demonstrating significant pain relief post-surgery.
Tech Giants’ Market Concentration Echoes Dot-Com Bubble Peak, Analysts Warn
Explore JPMorgan's analysis drawing parallels between today's US equity market and the dot-com bubble, highlighting the significant concentration of top stocks and sector dominance in the MSCI USA Index.
Marathon Petroleum Powers Ahead With Q4 Beat Despite Revenue, Profit Plunge: Details
MPC's robust Q4 FY23 performance reveals resilience, with revenue and other income reaching $36.82 billion, exceeding the $35.25 billion consensus. While income from operations dipped to $3.73 billion, adjusted EPS surged to $3.98, outpacing the expected $2.20. The company's strong financial position is evident with $10.2 billion in available funds.
Pfizer Surprises With Q4 Profit Despite Muted COVID Products Demand, Sticks To 2024 Guidance
Pfizer's Q4 2023 financial report: adjusted EPS beats estimates at $0.10, FY2023 EPS down 72%, Q4 sales decline 41% to $14.25B. CEO's positive outlook and reaffirmed 2024 guidance.
Weedkiller Woes: Australian Court Nears Decision in Bayer’s Roundup Trial
Follow the landmark Australian Roundup lawsuit against Bayer. Closing arguments in class action alleging Roundup's link to cancer.
Dealers Urge General Motors To Embrace Hybrids Amid Electric Vehicle Hesitancy
General Motors dealers voice concerns over exclusive focus on electric cars, urging hybrid models. Despite industry trends, GM executives remain non-committal.